Navigation Links
PAREXEL Reports Third Quarter Fiscal Year 2008 Financial Results
Date:4/23/2008

- Consolidated service revenue of $245.3 million grows 28% year-over-year

- Diluted earnings per share in the quarter were $0.25 - Backlog increases approximately 37% year-over-year to $1.9 billion; net

quarterly book-to-burn ratio equates to 1.52

BOSTON, April 23 /PRNewswire-FirstCall/ -- PAREXEL International Corporation (Nasdaq: PRXL) today announced its financial results for the third quarter and nine months ended March 31, 2008. The past and current period results reflect a two-for-one stock split which occurred on March 3, 2008.

For the three months ended March 31, 2008, PAREXEL's consolidated service revenue increased 28.3% to a record $245.3 million, compared with $191.2 million in the prior year period. The Company reported operating income of $22.7 million, or 9.3% of consolidated service revenue, in the third quarter of Fiscal Year 2008, versus operating income of $15.5 million, or 8.1% of consolidated service revenue, in the comparable quarter of the prior year. This represented a year-over-year increase of 46.8%. Included in these results was a favorable pre-tax restructuring benefit of $860,000 in the third quarter of Fiscal Year 2008, as noted in the financial charts contained within this press release. Net income for the quarter totaled $14.2 million, or $0.25 per diluted share, compared with net income of $10.8 million, or $0.19 per diluted share for the quarter ended March 31, 2007, an increase of 31.6%.

On a segment basis, consolidated service revenue for the third quarter of Fiscal Year 2008 consisted of $191.5 million in Clinical Research Services (CRS), $33.5 million in PAREXEL Consulting and Medical Communications (PCMS), and $20.3 million in Perceptive Informatics,
'/>"/>

SOURCE PAREXEL International Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. PAREXEL International to Present at Thomas Weisel Partners Healthcare Conference
2. Parexel Consulting Strengthens Good Manufacturing Practice Capabilities in Europe
3. PAREXEL International Completes Acquisition of APEX International Clinical Research Co., Ltd.
4. PAREXEL International Updates Financial Guidance in Conjunction with the Acquisition of APEX International Clinical Research Co., Ltd. and Other Factors
5. PAREXEL Announces Date of First Quarter Fiscal Year 2008 Earnings Release and Conference Call
6. PAREXEL Reports First Quarter Fiscal Year 2008 Financial Results
7. PAREXEL Appoints Charles A. Stevens as Vice President/General Manager of Health Policy and Strategic Reimbursement and Strengthens Capabilities
8. PAREXEL Announces Date of Second Quarter Fiscal Year 2008 Earnings Release and Conference Call
9. PAREXEL Names Biopharmaceutical Industry Executive Eduard E. Holdener to Board of Directors
10. PAREXEL Reports Second Quarter Fiscal Year 2008 Financial Results
11. PAREXEL International Announces 2-For-1 Stock Split
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... A study has been launched to test whether ... could help to tackle the problem of obesity.  This unique ... surgery based in Stowmarket) and academics at University Campus Suffolk ... technology, which is inspired by equipment used to collect data ...
(Date:1/15/2014)... The Microcompetition with Foreign DNA theory explains how latent ... viruses is the Epstein Barr Virus (EBV), and one of ... a chronic inflammatory disease that destroys the body’s joints. As ... have high concentrations of EBV DNA in their bodies (1). ...
(Date:1/15/2014)... Freeslate, Inc ., the leading provider ... Limited, one of India’s top five pharmaceutical companies, has ... for high throughput solid form screening. , ... wide range of quality, affordable generic and branded formulations ...
(Date:1/14/2014)... Date: Friday, April 11, 2014 , Time: 6 p.m. ... Road, Warrington, Pa. , Details: The Hepatitis B ... a cure for hepatitis B and improving the quality of ... Ball on Friday, April 11 at Warrington Country Club in ...
Breaking Biology Technology:Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 2Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 4Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3Hepatitis B Foundation to Host Annual Crystal Ball Gala 2
... STOCKHOLM, September 4 Karolinska Development (publ),today ... has,concluded an extensive clinical study of its candidate drug, ... labor during childbirth.,The promising results of the Phase II ... Karolinska Development,s business strategy. , ...
... BioSpecifics Technologies Corp. (Nasdaq: BSTC ), a ... that BioSpecifics, President, Tom Wegman, will present at the upcoming ... 10, 2009, at 12:05pm ET at the New York Palace ... A live webcast of the presentation can be accessed ...
... , , , , SAN ... the Company will present at the following investor conferences: , , ... 2:45 p.m. Eastern Time (ET) on September 9. , Thomas ... , The 2009 Morgan Stanley Global Healthcare Unplugged Conference in ...
Cached Biology Technology:Karolinska Development Portfolio Company Completes Successful Phase II Clinical Trial 2Karolinska Development Portfolio Company Completes Successful Phase II Clinical Trial 3Gen-Probe to Webcast Four Upcoming Investor Presentations 2
(Date:4/22/2014)... There are all sorts of signaling strategies in nature. ... tails; satin bowbirds build specialized stick structures, called bowers, ... European bitterling males show off bright nuptial coloration during ... to communicate with others. , ... profound fitness implications for individuals that are either signaling ...
(Date:4/22/2014)... must be aware of the broad patent landscape and ... a new paper from Rice University,s Baker Institute for ... the journal Regenerative Medicine , the paper is ... in the case Association for Molecular Pathology (AMP) v. ... court case and rulings garnered discussion in the public ...
(Date:4/22/2014)... have presented Beaumont Health System with prestigious, competitive ... both athletic and nonathletic injuries. , The ... $40,000 grant to fund stem cell-based research that ... a ruptured knee anterior cruciate ligament, or ACL. ... anterior cruciate ligament injury is the over-stretching or ...
Breaking Biology News(10 mins):Best practices in communication for the animal world 2Best practices in communication for the animal world 3New patenting guidelines are needed for biotechnology 2New patenting guidelines are needed for biotechnology 3Beaumont awarded grants to study sports-related injury treatment, improve recovery 2
... Patients with symptomatic moderate asthma who were treated ... antibody, experienced significantly fewer disease exacerbations than individuals ... the first issue for October 2006 of the ... published by the American Thoracic Society. , Trevor ...
... harnessing of 'T-rays' - electromagnetic terahertz waves - which ... varied as biological cell abnormalities and explosives has been announced. ... in Spain have said they have found a way to ... Their findings are set out in a letter published in ...
... theories regarding consciousness, emotion and quality of life ... (ALS, also known as 'Lou Gerhig's disease') are ... interaction. ALS is a progressive disease that destroys ... latest issue of Psychophysiology. The article reviews the ...
Cached Biology News:Monoclonal antibody reduces exacerbations in asthmatics 2T-ray breakthrough could make detecting disease far easier 2Computer with brain connections changing quality of life of paralyzed 2
Glutamate Receptor 5/1a...
Mouse monoclonal [3G8] to MDMA ( Abpromise for all tested applications)....
Fluorescein isothiocyanate (FITC) mouse anti-human IFN-alpha2 50 ug...
Dog polyclonal to Porcine Pancreatic Islets of Langerhans Cells ( Abpromise for all tested applications). Antigen: Tissue / cell preparation (Pig): Sonicated crude membrane fraction of porcine p...
Biology Products: